Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Feb 07, 2021
Mid-January Short Interest Report Shows 8 Stocks with Good Fundamentals and High Short Interest

Mid-January Short Interest Report Shows 8 Stocks with Good Fundamentals and High Short Interest

The most recent mania to hit the market seems to be stocks with high short interest. The huge spikes in Gamestop (GME) and AMC Entertainment (AMC) brought attention to an indicator that I’ve been using for 20 years. The most recent short interest reports recently came out and they are updated through January 15.

Some investors have been buying stocks simply because of their short interest level, but I am of the opinion that some stocks have such poor fundamentals that they should have high short interest levels. The stocks may rally over the short term, but in the end, the fundamentals are so bad that the company isn’t worth owning over the long term. These companies have seen earnings and revenue decline year after year and have poor profitability measurements.

Conversely, there are companies with high short interest levels that have strong fundamentals, have seen strong earnings and revenue growth, and have good profitability measurements. Companies that fit this description are much more appealing to me.

Once the new reports were published, I uploaded 37 stocks in to the Tickeron screener. These stocks were the ones with the highest percentage of short interest compared to the number of shares in the public float. From that list of 37 stocks, I isolated eight stocks that had an overall fundamental picture that I liked.

Of the eight stocks, the Tickeron scorecard has five with “strong buy” ratings, one with a “buy” rating, and two with “sell” ratings. The scorecard ratings are a combination of fundamental and technical analysis.

Several things jumped out at me about the eight stocks. First, all eight have received monthly bullish signals from Tickeron’s trend prediction tool over the last few days. Six of the eight signals have confidence levels over 80%. This suggests that these eight stocks have a high probability of moving higher over the next month.

The second thing that jumped out at me was the fact that six of the eight stocks have positive marks in one specific indicator that I rely on heavily—the SMR Rating. The only two stocks that don’t have a good SMR rating are Petmed Express (PETS) and National Beverage (FIZZ). Even those two companies have neutral readings in the category.

On the technical side, there are three areas where the majority of the stocks have received bullish signals of late. The three categories are the Aroon Indicator, the Momentum Indicator, and the Moving Average Indicator. All eight have received bullish signals from their Momentum Indicators in the last three weeks. Seven of the eight have received bullish signals from their Moving Average indicator without a single bearish signal. Seven of the eight have also received bullish signals from their Aroon Indicators with one bearish signal from National Beverage.

While I arrived at this list of stocks due to the short interest as a percentage of the float, there is another indicator that I like to look at as well and that is the short interest ratio. This indicator measures the number of shares sold short divided by the average daily trading volume. What this tells us is how long it will take short sellers to cover their positions based on the average daily volume.

My suggestion is to keep an eye on these stocks because if they start or continue to rally, the unwinding of the short positions can push the stock higher and higher.

Related Ticker: IRBT

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which engages in the business of designing and building robots

Industry HomeFurnishings

Profile
Details
Industry
Electronics Or Appliances
Address
8 Crosby Drive
Phone
+1 781 430-3000
Employees
1113
Web
https://www.irobot.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Mid-January Short Interest Report Shows 8 Stocks with Good Fundamentals and High Short Interest